Article
Patients with cystic fibrosis who could not receive the CFTR modulator treatment: What did they lose in 1 year?
Pediatric pulmonology - 1 Sept 2023
Uytun Salih, Cinel Güzin, Eryılmaz Polat Sanem, Özkan Tabakçı Satı, Kiper Nural, Yalçın Ebru, Ademhan Tural Dilber, Özsezen Beste, Şen Velat, Selimoğlu Şen Hadice, Ufuk Altıntaş Derya, Çokuğraş Haluk, Kılınç Ayşe Ayzıt, Başkan Azer Kılıç, Yazan Hakan, Çollak Abdulhamit, Uzuner Selçuk, Ünal Gökçen, Yılmaz Aslı İmran, Çağlar Hanife Tuğçe, Damadoğlu Ebru, Irmak İlim, Demir Esen, Kartal Öztürk Gökçen, Bingöl Ayşen, Başaran Erdem, Sapan Nihat, Canıtez Yakup, Tana Aslan Ayşe, Asfuroğlu Pelin, Harmancı Koray, Köse Mehmet, Hangül Melih, Özdemir Ali, Çobanoğlu Nazan, Özcan Gizem, Keskin Özlem, Yüksel Hasan, Özdoğan Şebnem, Topal Erdem, Çaltepe Gönül, Can Demet, Korkmaz Ekren Pervin, Kılıç Mehmet, Emiralioğlu Nagehan, Şişmanlar Eyüboğlu Tuğba, Pekcan Sevgi, Çakır Erkan, Özçelik Uğur, Doğru Deniz
Abstract excerpt
BACKGROUND: Cystic fibrosis (CF) is an autosomal recessive disorder caused by CF transmembrane conductance regulator (CFTR) genetic variants. CFTR modulators improve pulmonary function and reduce respiratory infections in CF. This study investigated the clinical and laboratory follow-up parameters over 1 year in patients with CF who could not receive this treatment. METHODS: This retrospective cohort study...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.